Noleus Technologies

Executive Summary

Noleus Technologies is a privately held medical device company headquartered in Boston, Massachusetts, developing innovative platform technologies to reduce post-surgical swelling and accelerate patient recovery. Founded in 2017, the company's lead product targets post-operative ileus (POI), a common complication following abdominal surgery characterized by bowel swelling and delayed return of gastrointestinal function. By mitigating bowel edema, Noleus aims to shorten hospital stays, reduce healthcare costs, and improve patient outcomes. The company is leveraging its proprietary platform to address other swelling-related surgical complications in the future, positioning itself within the drug delivery and medical device categories. Despite being in a competitive landscape, Noleus's focused approach on a high unmet medical need provides a clear value proposition. However, as a private entity with limited publicly disclosed operational details, including employee count, total funding, and clinical milestones, the company's exact development stage and financial runway remain uncertain. The absence of commercial products or FDA approvals suggests early-stage development, requiring successful clinical validation and regulatory navigation to achieve market entry.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial results for POI device30% success
• Q3 2026Series A or B funding round announcement50% success
• Q2 2027FDA breakthrough device designation or 510(k) submission40% success